Teleport (YC S15) | Backend Engineer | US, Europe, Canada, Remote OK | https://goteleport.com
Do you enjoy building security and deployment tools for other engineers?
Join us to hack on https://github.com/gravitational/teleport anywhere in the U.S, Canada and Europe.
Most of our code is Go, we have very little technical debt, our codebase is clean and small.
We expect you to be comfortable with the following: Go or Rust Linux, networking. Scalability or security experience for systems software is welcome.
We offer: Competitive salary and equity. 401k with company match. Excellent health insurance. Work anywhere in the U.S, Canada or Europe
Two radiation oncology trials presented at the IALSC World Conference on Lung Cancer Singapore highlight how some researchers are exploring use of higher radiation boost doses to only PET-positive regions in locally-advanced non-small cell lung cancer (NSCLC). A previous large RTOG phase III trial revealed that the unform delivery of a high dose to the entire tumor led to poorer survival.
SHARE
ESOU 2021: Reducing Morbidity of Inguinal Lymph Node Staging; New Developments in Inguinal Lymph Node Dissection and Sentinel Node Biopsy
(UroToday.com) The rare tumors session at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 Virtual meeting included a presentation discussing new developments in inguinal lymph node dissection and sentinel node biopsy, by Dr. Oscar Brouwer from The Netherlands Cancer Institute. Dr. Brouwer notes that penile cancer survival is highly dependent on lymph node status and that appropriate management of the regional lymph nodes is crucial for patient survival. Older studies suggest that early resection of occult metastasis versus resection after the disease is palpable during surveillance significantly improves cancer-specific survival (84% vs 35% at 3 years).
Insight into cancer cells own first aid could provide the basis for new immunotherapy
Insight into cancer cells own first aid could help the development of a new type of treatment. Johanna Olweus and her team at the UiO (University of Oslo) and the OUS (Oslo University Hospital) are important contributors to this study, which has been published in Nature.
Cancers such as malignant melanoma are notoriously difficult to treat. One of the reasons for this is the lack of good therapeutic targets, i.e. specific points for treatment to attack. Such points are ideally properties of the cancer cells that distinguish them from normal cells.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
January 26, 2021 GMT
NEW YORK & AMSTERDAM (BUSINESS WIRE) Jan 26, 2021
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.